YAP1 and melanoma: We demonstrate that YAP1/TAZ activity correlates positively with resistance to MAPKis across a large panel of melanoma cell lines in vitro, irrespective of additional genetic aberrations, and with the MITFlow/AXLhigh phenotype across melanoma cells lines and patient tumors, a subset of which acquires increased YAP1/TAZ activity along with MAPKi resistance.